🇺🇸 GW597599 in United States

3 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 3

Most-reported reactions

1. Atelectasis — 1 report (33.33%)
2. Chest Pain — 1 report (33.33%)
3. Unwanted Awareness During Anaesthesia — 1 report (33.33%)

Source database →

Frequently asked questions

Is GW597599 approved in United States?

GW597599 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GW597599 in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.